Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,285.13 +7.62 (+0.14%) Dow
38,618.91 -67.41 (-0.17%) Nasdaq
16,822.86 +87.84 (+0.52%) Bitcoin USD
69,763.71 +1,736.82 (+2.55%) CMC Crypto 200
1,503.67 +35.74 (+2.43%)
Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I (INDP)
| Previous close | 2.3700 |
| Open | 2.6300 |
| Bid | 1.9200 x 200 |
| Ask | 3.4600 x 200 |
| Day's range | 2.6300 - 2.8500 |
| 52-week range | 1.5600 - 4.0800 |
| Volume | |
| Avg. volume | 87,423 |
| Market cap | 22.714M |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7600 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireIndaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced updated data from its ongoing Phase 1 c
- GlobeNewswire
Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that Jeffrey Meckler, Chief Executive Officer, and Roger Waltzman, M.D., M.B.A., Chief Medical Officer, will present a corporate overview at the Jefferies Global Healthcare Conference. The conference is being held on June 5 – 6, 2024 at the Marriott Marquis in New York City. Presenta
- GlobeNewswire
Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
Poster abstract highlights response across multiple indicators of immune activation with rapid clearance of Decoy20NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces data from a poster being presented at the American Society of Clinical Oncology Annual Meeting 2024 on June 1. The conference will be held in Chicago at McCormick Place
